<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>21337345</Do_id>
  <Journal>Journal of surgical oncology</Journal>
  <Doc_title>Management of recurrent gastrointestinal stromal tumors.</Doc_title>
  <Doc_abstract>Recurrence after resection of primary gastrointestinal stromal tumor (GIST) is an unfortunately all-too-common phenomenon. The principal treatment for recurrent GIST is the first-line tyrosine kinase inhibitor (TKI) imatinib mesylate. Those who progress on, or are intolerant of imatinib, are treated with second-line TKI sunitinib malate. Cytoreductive surgery may be considered as an &quot;adjuvant&quot; therapy for patients with disease stabilized on imatinib, and, on an individual basis, sunitinib.</Doc_abstract>
  <Doc_ChemicalList>Benzamides;Indoles;Piperazines;Pyrimidines;Pyrroles;Imatinib Mesylate;sunitinib</Doc_ChemicalList>
  <Doc_meshdescriptors>Benzamides;Combined Modality Therapy;Gastrointestinal Neoplasms;Gastrointestinal Stromal Tumors;Humans;Imatinib Mesylate;Indoles;Neoplasm Recurrence, Local;Piperazines;Pyrimidines;Pyrroles</Doc_meshdescriptors>
  <Doc_meshqualifiers>therapy;therapy;therapeutic use;therapy;therapeutic use;therapeutic use;therapeutic use</Doc_meshqualifiers>
</Document>
